Since LCN2 inhibits ferroptosis in CRC cells by decreasing intracellular iron levels and stimulating the expression of GPX4 and xCT, elevated levels of LCN2 are associated with tumor progression and drug resistance. This evidence concerns the gene SLC7A11 and neoplasm.